International Collaborative Cancer Group (ICCG)

This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Collaborative Cancer Group (ICCG). Clinical trials include: Epirubicin plus tamoxifen versus tamoxifen alone in postmenopausal node-positive primary breast cancer. C/4/87Adjuvant cyclophosphamide methotrexate and 5-fluorouracil (CMF) versus 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in premenopausal node-positive primary breast cancer. (CMF/FEC N+). C/2/84Adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) versus 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in women with node-negative, poor-risk primary breast cancer. C/6/89Adjuvant FEC50 versus FEC75 with or without the additional benefit of sequential hormone therapy (HT) in node-positive premenopausal primary breast cancer. C/9/91High-dose therapy with PBCS support in primary breast cancer. C/10/92 – C/32/96Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2–3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen. BIG 02-97/Study No. 96 OEXE 031-C/13/96A multicentre-randomized trial of sequential epirubicin and docetaxel versus epirubicin in node-positive postmenopausal breast cancer patients. C/14/96A phase III multicentre double-blind randomized trial of celecoxib versus placebo in primary breast cancer patients. An intergroup study from the International Collaborative Cancer Group and the German Breast Group (GBG). BIG 1-03 – ICCG/C/20/01 – GBG 27